MA53937B1 - Compositions comprenant des souches bactériennes - Google Patents

Compositions comprenant des souches bactériennes

Info

Publication number
MA53937B1
MA53937B1 MA53937A MA53937A MA53937B1 MA 53937 B1 MA53937 B1 MA 53937B1 MA 53937 A MA53937 A MA 53937A MA 53937 A MA53937 A MA 53937A MA 53937 B1 MA53937 B1 MA 53937B1
Authority
MA
Morocco
Prior art keywords
compositions
bacterial strains
prevention
treatment
relates
Prior art date
Application number
MA53937A
Other languages
English (en)
Other versions
MA53937A (fr
Inventor
Imke Elisabeth MULDER
Suaad Ahmed
Helene Savignac
Anna Ettorre
Parthena Fotiadou
Samantha Yuille
Joseph Roby Iringan Urcia
Original Assignee
4D Pharma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1709468.1A external-priority patent/GB201709468D0/en
Priority claimed from GBGB1709534.0A external-priority patent/GB201709534D0/en
Priority claimed from GBGB1712851.3A external-priority patent/GB201712851D0/en
Priority claimed from GBGB1803826.5A external-priority patent/GB201803826D0/en
Priority claimed from GBGB1805990.7A external-priority patent/GB201805990D0/en
Priority claimed from GBGB1805989.9A external-priority patent/GB201805989D0/en
Priority claimed from GBGB1805991.5A external-priority patent/GB201805991D0/en
Priority claimed from GBGB1806779.3A external-priority patent/GB201806779D0/en
Priority claimed from GBGB1806780.1A external-priority patent/GB201806780D0/en
Application filed by 4D Pharma Res Ltd filed Critical 4D Pharma Res Ltd
Publication of MA53937A publication Critical patent/MA53937A/fr
Publication of MA53937B1 publication Critical patent/MA53937B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des compositions comprenant des souches bactériennes pour le traitement et la prévention de troubles neurodégénératifs.
MA53937A 2017-06-14 2018-06-14 Compositions comprenant des souches bactériennes MA53937B1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB1709468.1A GB201709468D0 (en) 2017-06-14 2017-06-14 Compositions comprising bacterial strains
GBGB1709534.0A GB201709534D0 (en) 2017-06-15 2017-06-15 Compositions comprising bacterial strains
GBGB1712851.3A GB201712851D0 (en) 2017-08-10 2017-08-10 Compositions comprising bacterial strains
GBGB1803826.5A GB201803826D0 (en) 2018-03-09 2018-03-09 Compositions comprising bacterial strains
GBGB1805990.7A GB201805990D0 (en) 2018-04-11 2018-04-11 Compostions comprising bacterial strains
GBGB1805989.9A GB201805989D0 (en) 2018-04-11 2018-04-11 Compositions comprising bacterial strains
GBGB1805991.5A GB201805991D0 (en) 2018-04-11 2018-04-11 Compositions comprising bacterial strains
GBGB1806779.3A GB201806779D0 (en) 2018-04-25 2018-04-25 Compositions comprising bacterial strains
GBGB1806780.1A GB201806780D0 (en) 2018-04-25 2018-04-25 Compositions comprising bacterial strains

Publications (2)

Publication Number Publication Date
MA53937A MA53937A (fr) 2021-04-14
MA53937B1 true MA53937B1 (fr) 2022-05-31

Family

ID=62784100

Family Applications (3)

Application Number Title Priority Date Filing Date
MA049425A MA49425A (fr) 2017-06-14 2018-06-14 Compositions comprenant des souches bactériennes
MA53937A MA53937B1 (fr) 2017-06-14 2018-06-14 Compositions comprenant des souches bactériennes
MA49010A MA49010B1 (fr) 2017-06-14 2018-06-14 Compositions comprenant une souche bactérienne du genre megasphaera et leurs utilisations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA049425A MA49425A (fr) 2017-06-14 2018-06-14 Compositions comprenant des souches bactériennes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA49010A MA49010B1 (fr) 2017-06-14 2018-06-14 Compositions comprenant une souche bactérienne du genre megasphaera et leurs utilisations

Country Status (25)

Country Link
US (3) US11660319B2 (fr)
EP (4) EP3804737B1 (fr)
JP (4) JP6837581B2 (fr)
KR (2) KR20200015575A (fr)
CN (2) CN111032061A (fr)
AU (4) AU2018285453B2 (fr)
BR (2) BR112019026667A2 (fr)
CA (3) CA3066557A1 (fr)
CY (2) CY1123565T1 (fr)
DK (2) DK3600364T3 (fr)
ES (2) ES2917415T3 (fr)
HR (2) HRP20220747T1 (fr)
HU (2) HUE059249T2 (fr)
IL (3) IL292373A (fr)
LT (2) LT3600364T (fr)
MA (3) MA49425A (fr)
MD (2) MD3600364T2 (fr)
MX (1) MX2021006456A (fr)
PL (2) PL3600364T3 (fr)
PT (2) PT3804737T (fr)
RS (2) RS63393B1 (fr)
SG (2) SG11201912153VA (fr)
SI (2) SI3804737T1 (fr)
TW (2) TWI812624B (fr)
WO (2) WO2018229216A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220747T1 (hr) 2017-06-14 2022-10-14 4D Pharma Research Limited Pripravci koji sadrže bakterijske sojeve
KR20210008393A (ko) * 2018-05-11 2021-01-21 4디 파마 리서치 리미티드 세균 균주를 포함하는 조성물
EP3893905A1 (fr) * 2018-12-12 2021-10-20 4D Pharma Research Limited Compositions comprenant des souches bactériennes
JP2022535761A (ja) * 2019-06-03 2022-08-10 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 敗血症および壊死性腸炎誘発神経発達不全の予防のためのプレバイオティクス製剤
CN114615971A (zh) 2019-07-05 2022-06-10 4D制药研究有限公司 包含细菌菌株的组合物
CN110420228A (zh) * 2019-09-16 2019-11-08 山东大学齐鲁医院 脆弱拟杆菌ych46在制备治疗或辅助治疗高血压的药物中的应用
EP4034096A1 (fr) * 2019-09-25 2022-08-03 Philipps-Universität Marburg Pentanoate d'acide gras à chaîne courte en tant qu'activateur pour une thérapie cellulaire et une thérapie antitumorale
AU2021342481A1 (en) 2020-09-18 2023-05-04 Evelo Biosciences, Inc. Solid dosage forms of bacteria
CN112239741B (zh) * 2020-12-10 2022-05-27 慕恩（广州）生物科技有限公司 一种Megasphaera属的细菌MNC-992及其培养方法和应用
WO2022132738A1 (fr) 2020-12-14 2022-06-23 Evelo Biosciences, Inc. Préparations de vésicules extracellulaires
TW202302125A (zh) 2021-03-05 2023-01-16 美商艾弗洛生物科技股份有限公司 固體劑型
JP2024516110A (ja) 2021-04-08 2024-04-12 エヴェロ バイオサイエンシズ，インコーポレーテッド 細菌を含有する医薬組成物
CN117545496A (zh) * 2021-05-12 2024-02-09 生物米卡有限公司 微生物同生菌群及其用途
KR20240093504A (ko) 2021-09-24 2024-06-24 에벨로 바이오사이언시즈, 인크. 박테리아 및 미생물 세포외 소포를 함유하는 고체 투여 형태
CN114276948B (zh) * 2021-11-08 2023-06-20 泸州老窖股份有限公司 产己酸的赖氨酸芽孢杆菌及其用途
WO2023107537A1 (fr) 2021-12-07 2023-06-15 Evelo Biosciences, Inc. Compositions d'anticorps et procédés d'utilisation avec des vésicules extracellulaires et microbes
WO2023114296A2 (fr) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Préparations de vésicules extracellulaires
WO2024015522A1 (fr) 2022-07-13 2024-01-18 Evelo Biosciences, Inc. Procédés d'analyse de vésicules extracellulaires et de microbes
WO2024076723A1 (fr) 2022-10-07 2024-04-11 Evelo Biosciences, Inc. Traitement de vésicules extracellulaires
WO2024102226A1 (fr) 2022-10-14 2024-05-16 Evelo Biosciences, Inc. Procédés de dosage de substances médicamenteuses et de produits médicamenteux à l'aide de lignées cellulaires comportant des gènes rapporteurs inductibles par nf-kb

Family Cites Families (405)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
JPS5031249B1 (fr) 1970-12-17 1975-10-08
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
JPS5710876B2 (fr) 1974-04-08 1982-03-01
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4138498A (en) * 1976-12-07 1979-02-06 W. R. Grace & Co. Ruminant feed additive
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
JPS5557520A (en) 1978-10-26 1980-04-28 Nisshin Flour Milling Co Ltd Preparation of carcinostatic substance
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
KR100225087B1 (ko) 1990-03-23 1999-10-15 한스 발터라벤 피타아제의 식물내 발현
ES2068586T5 (es) 1990-05-09 2004-12-01 Novozymes A/S Una preparacion de celulasa que comprende una enzima endoglucanasa.
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
EP0581171B1 (fr) 1992-07-20 1998-02-04 Kabushiki Kaisha Yakult Honsha Oligonucléotides spécifiques des espèces des bifidobactéries et procédé de détection les utilisant
DK0673429T3 (da) 1992-12-10 2002-10-07 Dsm Nv Fremstilling af heterologe proteiner i filamentøse svampe
US5741665A (en) 1994-05-10 1998-04-21 University Of Hawaii Light-regulated promoters for production of heterologous proteins in filamentous fungi
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM823094A0 (en) 1994-09-16 1994-10-13 Goodman Fielder Limited Probiotic compositions
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
RU2078815C1 (ru) 1995-01-17 1997-05-10 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Штамм бактерий bifidobacterium breve, используемый для получения бактерийных лечебно-профилактических бифидосодержащих препаратов
JPH08259450A (ja) 1995-03-17 1996-10-08 Nichinichi Seiyaku Kk インターフェロン産生増強剤
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
CA2232001C (fr) * 1995-09-15 2002-12-10 Dale N. Gerding Procedes et compositions pour prevenir et traiter les maladies associees a clostridium difficile
AUPN698495A0 (en) 1995-12-06 1996-01-04 Pharma Pacific Pty Ltd Improved therapeutic formulation and method
SE508045C2 (sv) 1996-02-26 1998-08-17 Arla Ekonomisk Foerening Adhesionsinhibitorer, preparat innehållande desamma och förfarande för framställning därav
ATE407700T1 (de) 1996-03-20 2008-09-15 Univ New South Wales Veränderung der mikrobenflora im verdauungstrakt
AUPN881396A0 (en) 1996-03-20 1996-04-18 Arnott's Biscuits Limited Enhancement of microbial colonization of the gastrointestinal tract
WO1997035956A1 (fr) 1996-03-27 1997-10-02 Novo Nordisk A/S Champignons filamenteux carences en proteases alcalines
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
WO1998043081A1 (fr) 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Traitement de troubles gastro-intestinaux au moyen de modulateurs du recepteur active de la proliferation des peroxysomes (ppar)
SE511524C2 (sv) 1997-06-02 1999-10-11 Essum Ab Lactobacillus casei rhamnosus-stam samt farmaceutisk beredning för bekämpning av patogena tarmbakterier
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
US6652866B1 (en) 1997-10-14 2003-11-25 David W. Hertha Method for treating diseases of fungal, yeast, and prion protein etiology
IT1298918B1 (it) 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
DE19826928A1 (de) 1998-06-17 1999-12-23 Novartis Consumer Health Gmbh Arzneimittel, lebensfähige anaerobe Bakterien enthaltend, die die Sulfatreduktion sulfatreduzierender Bakterien hemmen
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7090973B1 (en) 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
AUPQ137699A0 (en) * 1999-07-02 1999-07-22 University Of New England, The Control of acidosis
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
EP1257176B1 (fr) 2000-02-08 2008-04-30 DSM IP Assets B.V. Utilisation de proteases a acidite stable dans l'alimentation animale
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AU2002226984A1 (en) 2000-11-27 2002-06-03 Astrazeneca Ab Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon
BR0116788A (pt) * 2000-12-21 2004-02-03 Nestle Sa Cepa de lactobacillus que produz levano e seu uso em produtos alimentìcios para seres humanos ou para animais de estimação
DE10101793A1 (de) 2001-01-17 2002-08-01 Manfred Nilius Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen
EP1227152A1 (fr) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Souche bactérienne et genome de bifidobacterium
KR100437497B1 (ko) 2001-03-07 2004-06-25 주식회사 프로바이오닉 로타바이러스 및 유해 미생물 억제 활성을 가지는 신규내산성 락토바실러스 루테리 프로바이오-16 및 이를함유하는 생균활성제
EP1243273A1 (fr) 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition contenant un agent prebiotique pour le traitement d'inflammation et d'activation anormal des agents immunitaires non-spécifiques
WO2002080947A1 (fr) 2001-04-06 2002-10-17 Kyodoken Institute For Animal Science Research & Development Compositions contenant une bacterie pouvant convertir de l'acide lactique en acide butyrique, et methode utilisant ces compositions pour prevenir ou traiter l'hyperlactacidemie dans le systeme digestif ou le cancer du colon
ATE463505T1 (de) 2001-04-20 2010-04-15 Inst Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
EP1260227A1 (fr) 2001-05-23 2002-11-27 Societe Des Produits Nestle S.A. L'acide lipoteichoique des bacteries lactiques et son utilisation pour moduler des responses immunitaites induites par des bacteries a gram negatif, gram positif
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
US20040241149A1 (en) 2001-09-05 2004-12-02 Claudio De Simone Use of unmethylatd cpg
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20050037955A1 (en) 2001-11-27 2005-02-17 Hooper Laura Virginia Therapeutic protein and treatments
CA2860702C (fr) 2001-12-17 2019-02-26 Corixa Corporation Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
DE10206995B4 (de) 2002-02-19 2014-01-02 Orthomol Pharmazeutische Vertriebs Gmbh Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
JP2003261453A (ja) 2002-03-11 2003-09-16 Nippon Berumu Kk Ｅ．フェカリスからなる抗腫瘍剤及び放射線防護剤
EP1565547B2 (fr) 2002-06-28 2012-09-19 Biosearch S.A. Souches probiotiques, leur procede de selection, compositions associees et leur utilisation
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
US20040230963A1 (en) * 2003-05-12 2004-11-18 Rothman Michael A. Method for updating firmware in an operating system agnostic manner
EP1481681A1 (fr) 2003-05-30 2004-12-01 Claudio De Simone Combinaisons de bactéries lactiques et leur compositions
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
AU2003247193A1 (en) 2003-07-23 2005-02-04 M.D.Lab Corp. Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus
US7485325B2 (en) 2003-08-06 2009-02-03 Gayle Dorothy Swain Animal food supplement compositions and methods of use
JP4683881B2 (ja) 2003-08-27 2011-05-18 有限会社アーク技研 抗腫瘍活性剤
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
EP2226072A1 (fr) * 2003-08-29 2010-09-08 Aton Pharma, Inc. Combinaisons à base d'acide suberoylanilide hydroxamique et d'agents antimétabolites pour le traitement du cancer
US20050163764A1 (en) 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
GB0323039D0 (en) 2003-10-01 2003-11-05 Danisco Method
PT1675481E (pt) 2003-10-24 2009-01-02 Nutricia Nv Composição sinbiótica para bebés
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
EP1696941A1 (fr) 2003-12-17 2006-09-06 N.V. Nutricia Bacteries produisant de l'acide lactique et la fonction pulmonaire
ES2235642B2 (es) 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
CN1954066A (zh) 2004-03-22 2007-04-25 美国政府健康及人类服务部 细胞和病毒灭活
WO2005107381A2 (fr) 2004-05-07 2005-11-17 Hans-Gustaf Ljunggren Adjuvants
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
EP1765391B1 (fr) 2004-06-07 2013-03-06 Qu Biologics Inc Compositions bacteriennes pour le traitement d'un cancer
ES2523018T3 (es) 2004-06-30 2014-11-20 Nutrition Sciences N.V./S.A. Ácidos grasos de cadena media aplicables como agentes anti-microbianos
ATE361101T1 (de) 2004-08-24 2007-05-15 Nutricia Nv Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
US20060062773A1 (en) 2004-09-21 2006-03-23 The Procter & Gamble Company Compositions for maintaining and restoring normal gastrointestinal flora
JP5371169B2 (ja) 2004-09-24 2013-12-18 コンビ株式会社 薬剤耐性菌感染防除剤
KR100468522B1 (ko) 2004-10-12 2005-01-31 주식회사 프로바이오닉 코로나바이러스와 돼지 써코바이러스 2형의 생육을 억제하는 신규한 내산성 프로바이오틱 엔테로코커스훼시움 프로바이오-63
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
ITMI20042189A1 (it) 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
US20060194241A1 (en) 2005-02-28 2006-08-31 Jan Knol Lactobacillus specific probes
WO2006102536A2 (fr) 2005-03-23 2006-09-28 University Of Southern California Traitement d'etats pathologiques par modulation du sulfure d'hydrogene produit par la proliferation bacterienne de l'intestin grele
WO2006102350A1 (fr) 2005-03-23 2006-09-28 Washington University In St. Louis Utilisation d'archees pour moduler les fonctions de capture des nutriments par la microbiote gastro-intestinale
JP2006265212A (ja) 2005-03-25 2006-10-05 Institute Of Physical & Chemical Research Ｉｌ−２１産生誘導剤
US20100233312A9 (en) 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
EP1714660A1 (fr) 2005-04-21 2006-10-25 N.V. Nutricia D'acide uronique et des probiotiques
DK1874917T3 (da) 2005-04-26 2012-05-14 Teagasc Agric Food Dev Authori Probiotisk sammensætning, der er egnet til dyr
CN101213297B (zh) 2005-05-09 2013-02-13 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
US7572474B2 (en) 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US8075934B2 (en) 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
JP2007084533A (ja) 2005-08-24 2007-04-05 Prima Meat Packers Ltd 免疫応答調節組成物及び該組成物を有効成分とする食品
US7625704B2 (en) 2005-08-31 2009-12-01 Fred Hutchinson Cancer Research Center Methods and compositions for identifying bacteria associated with bacteria vaginosis
EP1933869B1 (fr) 2005-09-01 2009-10-14 Schering Corporation Utilisation d'antagonistes de l'il-23 et de l'il-17 pour le traitement de la maladie inflammatoire oculaire auto-immune
US20090028840A1 (en) 2005-09-23 2009-01-29 Gwangju Institute Of Sciecne And Technology Compositions For Preventing Or Treating Arthritis Comprising Lactic Acid Bacteria and Collangen As Active Ingredients
EP1776877A1 (fr) 2005-10-21 2007-04-25 N.V. Nutricia Méthode de stimulation de la flore intestinale
WO2007050656A2 (fr) 2005-10-24 2007-05-03 Nestec S.A. Preparation de fibres alimentaires et leur methode d'administration
JP2007116991A (ja) 2005-10-28 2007-05-17 Eternal Light General Institute Inc 機能性食品
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7553864B2 (en) 2005-12-01 2009-06-30 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
US8889149B2 (en) 2006-02-16 2014-11-18 Wayne State University Use of flagellin to prevent and treat gram negative bacterial infection
US20080260906A1 (en) 2006-03-17 2008-10-23 Marko Stojanovic Compositions comprising probiotic and sweetener components
JP5031249B2 (ja) 2006-03-22 2012-09-19 学校法人北里研究所 炎症抑制作用のある菌体含有組成物
US20090252708A1 (en) 2006-05-18 2009-10-08 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
MY147954A (en) 2006-05-26 2013-02-15 Nestec Sa Methods of use and nutritional compositions of touchi extract
CA2654457A1 (fr) 2006-06-06 2007-12-13 Mcgill University Produit de lait fermente et son utilisation
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
AU2007280272A1 (en) 2006-08-04 2008-02-07 Shs International Ltd Protein free formula
WO2008031438A2 (fr) 2006-09-13 2008-03-20 Region Hovedstaden V/Gentofte Hospital Traitement de l'asthme, de l'eczéma et / ou d'allergies à l'aide d'organismes non pathogènes
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
ES2895666T3 (es) 2006-10-27 2022-02-22 Capsugel Belgium Nv Cápsulas duras de hidroxipropilmetilcelulosa y proceso de fabricación
WO2008053444A2 (fr) 2006-11-01 2008-05-08 The Procter & Gamble Company Méthodes visant à traiter un trouble respiratoire au moyen d'un traitement probiotique
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
WO2008064489A1 (fr) 2006-12-01 2008-06-05 Mcmaster University Probiotiques destinés à inhiber les inflammations
US20100172874A1 (en) 2006-12-18 2010-07-08 The Washington University Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
WO2008083157A2 (fr) 2006-12-29 2008-07-10 Washington University In St. Louis Altération du pgc-1alpha, de l'ampk, du fiaf, ou du microbiote gastro-intestinal comme moyen pour moduler les réserves lipidiques de l'organisme et/ou la perte de poids chez un sujet
JP2008195635A (ja) 2007-02-09 2008-08-28 Crossfield Bio Inc 馬用乳酸菌製剤
ATE544457T1 (de) 2007-02-28 2012-02-15 Mead Johnson Nutrition Co Verfahren zur behandlung bzw. prävention systemischer entzündungen
CN101679938B (zh) 2007-03-28 2014-03-19 营养健康有限公司 益生双歧杆菌菌株
US8557233B2 (en) 2007-03-28 2013-10-15 Alimentary Heath Limited Probiotic bifidobacterium strains
EP2147091A4 (fr) 2007-04-24 2010-12-08 Kemin Ind Inc Activité antibactérienne et antifongique à spectre large de lactobacillus johnsonii d115
EP1997499A1 (fr) 2007-05-31 2008-12-03 Puleva Biotech, S.A. Microorganismes de lait maternel, compositions les contenant et leur utilisation pour le traitement de métastase
EP1997905A1 (fr) 2007-06-01 2008-12-03 Friesland Brands B.V. Amplification d'acide nucléique
EP1997906A1 (fr) 2007-06-01 2008-12-03 Friesland Brands B.V. Lactobacillus
EP1997907A1 (fr) 2007-06-01 2008-12-03 Friesland Brands B.V. Bifidobactéries
WO2008153377A1 (fr) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition avec une bifidobactérie non viable et un oligosaccharide non digestible
WO2009002145A1 (fr) 2007-06-26 2008-12-31 N.V. Nutricia Composition lipidique destinée à améliorer l'activité cérébrale
WO2009000899A1 (fr) 2007-06-27 2008-12-31 Laboratorios Ordesa, S.L. Nouvelle souche de bifidobactérie et peptides actifs contre des infections par un rotavirus
HUP0700552A2 (en) 2007-08-27 2009-03-30 Janos Dr Feher Method and composition inhibiting inflammation
WO2009030254A1 (fr) 2007-09-04 2009-03-12 Curevac Gmbh Complexes d'arn et de peptides cationiques pour transfection et immunostimulation
EP2192909A2 (fr) 2007-10-01 2010-06-09 University College Cork-National University of Ireland, Cork Modulation de la composition en acides gras tissulaires d'un hôte par des bactéries de l'intestin humain
EP2203551B1 (fr) 2007-10-20 2013-08-21 Université de Liège Espèce bifidobactérienne
WO2009055362A1 (fr) 2007-10-26 2009-04-30 Moore Brenda E Compositions probiotiques et procédés pour induire et maintenir une perte de poids
EP2205642B1 (fr) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Compositions de polysaccharides non anticoagulants
EP2065048A1 (fr) 2007-11-30 2009-06-03 Institut Pasteur Utilisation d'une souche de L. casei pour la préparation d'une composition pour l'inhibition de l'activation de mastocytes
EP2898889B1 (fr) 2007-12-07 2017-03-22 N.V. Nutricia Bifidobactrium pour traiter l'allergie aux acariens de la poussière
US20100330190A1 (en) 2007-12-17 2010-12-30 Compans Richard W Immunogenic compositions and methods of use thereof
ES2343499B1 (es) 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
CN101939411A (zh) 2008-02-06 2011-01-05 宝洁公司 用于提高呼吸病症免疫应答的组合物、方法和试剂盒
EP2103226A1 (fr) 2008-03-18 2009-09-23 Friesland Brands B.V. Produit alimentaire probiotique de longue durée
JP2011519828A (ja) 2008-04-18 2011-07-14 バクシネート コーポレーション フラジェリンの欠失変異体と使用方法
US8741365B2 (en) 2008-05-13 2014-06-03 Glycotope Gmbh Fermentation process
MX2008006546A (es) 2008-05-21 2009-11-23 Sigma Alimentos Sa De Cv Bifidobacteria productora de ácido fólico, composición alimenticia y uso de la bifidobacteria.
CN102940652B (zh) 2008-05-28 2015-03-25 青岛东海药业有限公司 两形真杆菌制剂及其应用
CN101590081A (zh) 2008-05-28 2009-12-02 青岛东海药业有限公司 凸腹真杆菌和两形真杆菌制剂及其应用
US8586029B2 (en) 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
CN101596216A (zh) * 2008-06-06 2009-12-09 萧湘 预防或治疗糖尿病和相关病症的微生物制剂
EP2133088A3 (fr) 2008-06-09 2010-01-27 Nestec S.A. Rooibos et inflammation
WO2009151315A1 (fr) 2008-06-13 2009-12-17 N.V. Nutricia Composition nutritionnelle pour nourrissons nés par césarienne
WO2009154463A2 (fr) 2008-06-20 2009-12-23 Stichting Top Institute Food And Nutrition Le butyrate comme médicament permettant d'améliorer la perception viscérale chez l'homme
EP2138186A1 (fr) 2008-06-24 2009-12-30 Nestec S.A. Probiotiques, IgA de sécrétion et inflammation
WO2010002241A1 (fr) 2008-06-30 2010-01-07 N.V. Nutricia Composition nutritive pour bébés nés par césarienne
KR101017448B1 (ko) 2008-09-18 2011-02-23 주식회사한국야쿠르트 대장의 건강 증진 효능을 갖는 비피도박테리움 롱검 에이취와이8004 및 이를 유효성분으로 함유하는 제품
US20100074870A1 (en) 2008-09-19 2010-03-25 Bristol-Myers Squibb Company Probiotic infant products
US8137718B2 (en) 2008-09-19 2012-03-20 Mead Johnson Nutrition Company Probiotic infant products
KR101057357B1 (ko) 2008-09-22 2011-08-17 광주과학기술원 유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물
WO2010036876A2 (fr) 2008-09-25 2010-04-01 New York University Compositions et procédés de caractérisation et de restauration du microbiote gastro-intestinal, cutané et nasal
WO2010037408A1 (fr) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprenant un arnm complexé et un arnm nu pour déclencher ou augmenter une réponse immunostimulante chez un mammifère et utilisations de ladite composition
WO2010037402A1 (fr) 2008-10-02 2010-04-08 Dako Denmark A/S Vaccins moléculaires contre les maladies infectieuses
WO2010063601A1 (fr) 2008-12-05 2010-06-10 Nestec S.A. Compositions pour utilisation chez des nourrissons à faible poids à la naissance
BRPI0923171A2 (pt) 2008-12-19 2015-08-11 Nestec Sa Prevenção e tratamento da diarréia causada por rotavírus.
IT1392672B1 (it) 2009-01-12 2012-03-16 Wyeth Consumer Healthcare S P A Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
JP5710876B2 (ja) 2009-03-26 2015-04-30 クロスフィールドバイオ株式会社 新規ビフィドバクテリウム属微生物およびその利用
JP6077303B2 (ja) 2009-05-07 2017-02-08 タト エ リル アングルディアント フランス ソシエテ パ アクシオンス シンプリフィエ アルファ−（１，２）−分岐アルファ−（１，６）オリゴデキストランを含有する組成物及びアルファ−（１，２）−分岐アルファ−（１，６）オリゴデキストランの製造方法
EP2251022A1 (fr) 2009-05-11 2010-11-17 Nestec S.A. Micro-organismes sans réplication, et leur effet d'augmentation immunitaire
EP2251020A1 (fr) 2009-05-11 2010-11-17 Nestec S.A. Traitement haute température de courte durée qui génère des préparations microbiennes avec des profils anti-inflammatoires
JP2012526752A (ja) 2009-05-11 2012-11-01 ネステク ソシエテ アノニム ビフィドバクテリウム・ロンガムｎｃｃ２７０５（ｃｎｃｍｉ−２６１８）及び免疫障害
KR20100128168A (ko) 2009-05-27 2010-12-07 중앙대학교 산학협력단 공액 리놀레산 생산능이 우수한 신규한 균주
US20100311686A1 (en) 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
WO2010143940A1 (fr) 2009-06-12 2010-12-16 N.V. Nutricia Mélange synergique de bêta-galacto-oligosaccharides avec des liaisons bêta-1,3 et bêta-1,4/1,6
WO2010147714A1 (fr) 2009-06-16 2010-12-23 The Trustees Of Columbia University In The City Of New York Biomarqueurs associés à l'autisme et utilisations de ces derniers
US9050276B2 (en) * 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
WO2011005756A1 (fr) 2009-07-06 2011-01-13 Puretech Ventures, Llc Administration d'agents ciblés contre des niches de microbiote
EP2456891A4 (fr) 2009-07-24 2013-04-03 Southwest Regional Pcr Llc Diagnostic, détection, quantification microbiens universels, et thérapie ciblée sur un échantillon
SG178167A1 (en) 2009-08-18 2012-03-29 Nestec Sa A nutritional composition comprising bifidobacterium longum strains and reducing food allergy symptoms, especially in infants and children
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
GB2473294B (en) 2009-09-08 2014-07-09 Mclaren Automotive Ltd Dynamics control
PL2480255T3 (pl) 2009-09-23 2018-07-31 Thomas Julius Borody Terapia przewlekłych zakażeń jelitowych
EP2308498A1 (fr) 2009-09-30 2011-04-13 Nestec S.A. Administration de bifidobacterium rapide au cours de l'enfance pour empêcher une inflammation postérieure au cours de la vie
US20120238468A1 (en) 2009-10-05 2012-09-20 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
WO2011044208A1 (fr) 2009-10-06 2011-04-14 Scott Dorfner Formulations antibiotiques exerçant des effets secondaires gastro-intestinaux réduits
CA2779418C (fr) 2009-11-11 2018-03-20 Alimentary Health Limited Souche de bifidobacterium probiotique
MY162183A (en) 2009-12-01 2017-05-31 Univ Putra Malaysia Probiotic composition for nutraceutical product
RU2533024C2 (ru) 2009-12-18 2014-11-20 Хилл`С Пет Ньютришн, Инк. Композиции кормовых продуктов для домашних животных, включающие пробиотики, способы их получения и применение
JP5557520B2 (ja) 2009-12-22 2014-07-23 京楽産業．株式会社 遊技機の演出用動力伝達機構及びこれを備える遊技機
US20150104418A1 (en) 2014-12-18 2015-04-16 Microbios, Inc. Bacterial composition
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
NL2004200C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
JP5737646B2 (ja) 2010-03-24 2015-06-17 森下仁丹株式会社 抗アレルギー剤
WO2011121379A1 (fr) 2010-03-30 2011-10-06 Assistance Publique - Hopitaux De Paris Utilisation de bifidobactéries pour prévenir les allergies chez les enfants nourris au sein
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011149335A1 (fr) 2010-05-25 2011-12-01 N.V. Nutricia Composition nutritionnelle d'empreinte immunitaire
KR20130086155A (ko) 2010-06-01 2013-07-31 무어 리서치 엔터프라이지스 엘엘씨 박테로이데스로부터의 세포 성분, 그의 조성물, 및 박테로이데스 또는 그의 세포 성분을 이용하는 치료 방법
WO2011151941A1 (fr) 2010-06-04 2011-12-08 国立大学法人東京大学 Composition présentant une activité d'induction de la prolifération ou de l'accumulation de cellule t régulatrice
TWI417054B (zh) 2010-06-15 2013-12-01 Jen Shine Biotechnology Co Ltd 新穎糞腸球菌ｌｊｓ－０１及其益生用途
EP2397145A1 (fr) 2010-06-18 2011-12-21 Nestec S.A. L. johnsonii La1, B. longum NCC2705 et troubles immunitaires
FR2962045B1 (fr) 2010-07-05 2012-08-17 Bifinove Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires
CN101914452B (zh) * 2010-07-14 2011-12-07 洪亚辉 石杉碱甲高产菌株tcm-01
TWI401086B (zh) 2010-07-20 2013-07-11 Univ China Medical 胚芽乳酸桿菌及其用途
KR102157718B1 (ko) 2010-07-26 2020-09-18 큐 바이올로직스 인코포레이티드 면역원성 소염 조성물
AU2011286165B2 (en) 2010-08-04 2016-10-20 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
WO2012024638A2 (fr) 2010-08-20 2012-02-23 New York University Compositions et méthodes de traitement de l'obésité et de troubles associés par la caractérisation et la restauration du microbiote bactérien de mammifère
KR101250463B1 (ko) 2010-10-12 2013-04-15 대한민국 신생아 분변에서 분리한 내산소성 비피도박테리움 롱검 비피더스 유산균 및 이를 이용한 프로바이오틱 조성물
WO2012055408A1 (fr) 2010-10-27 2012-05-03 Quantibact A/S Capture d'adn et d'arn cibles par des sondes comprenant des molécules intercalaires
CN102031235B (zh) 2010-11-09 2012-07-25 中国农业大学 一种粪肠球菌anse228及其应用
EP2455092A1 (fr) 2010-11-11 2012-05-23 Nestec S.A. Protection de micro-organismes probiotiques sans réplication contre les infections des voies respiratoires supérieures
US20120128644A1 (en) 2010-11-24 2012-05-24 Oragenics, Inc. Use of Bacteria to Treat and Prevent Respiratory Infections
CN102093967B (zh) 2010-12-02 2013-01-30 中国农业科学院特产研究所 一株水貂源屎肠球菌及其应用
ES2389547B1 (es) 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
AU2012205681B2 (en) 2011-01-10 2016-07-28 Cleveland Biolabs, Inc. Use of toll-like receptor agonist for treating cancer
PT2481299T (pt) 2011-01-31 2017-03-08 Synformulas Gmbh Estirpes de bifidobacterium bifidum para aplicação em doenças gastrointestinais
JP5840368B2 (ja) 2011-02-02 2016-01-06 カルピス株式会社 関節炎予防改善用物質
PL2672980T3 (pl) 2011-02-09 2018-05-30 Lavivo Ab Synbiotyczne kompozycje dla odnowienia i odtworzenia flory bakteryjnej jelita
EP3610881A1 (fr) 2011-03-09 2020-02-19 Regents Of The University Of Minnesota Compositions et procédés de transplantation du microbiome du colon
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
WO2012140636A1 (fr) 2011-04-11 2012-10-18 Alimentary Health Limited Formulation probiotique
WO2012142605A1 (fr) 2011-04-15 2012-10-18 Samaritan Health Services Agent de déploiement de recolonisation rapide
EA201391553A1 (ru) 2011-04-20 2014-03-31 Майко Байо, Инк. Композиция и способ усиления иммунного ответа
US9567361B2 (en) 2011-05-13 2017-02-14 Glycosyn LLC Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
KR20120133133A (ko) 2011-05-30 2012-12-10 한국 한의학 연구원 생약 추출물 또는 이의 유산균 발효물을 포함하는 호흡기 질환의 예방 또는 치료용 조성물
US20140171339A1 (en) 2011-06-06 2014-06-19 The University Of North Carolina At Chapel Hill Methods and kits for detecting adenomas, colorectal cancer, and uses thereof
GB201110095D0 (en) 2011-06-15 2011-07-27 Danisco Method of treatment
US9579353B2 (en) * 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
JP2013005759A (ja) 2011-06-24 2013-01-10 Kyodo Milk Industry Co Ltd マウス腸内菌叢の推測方法
CN102408998B (zh) * 2011-06-28 2013-06-05 深圳大学 一种具有神经退行性疾病防治活性的海洋红树耐盐性内生真菌
US20140128585A1 (en) 2011-07-07 2014-05-08 Nagaoka Perfumery Co., Ltd. Fructose absorption inhibitor
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
WO2013008102A2 (fr) 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Procédés et compositions pour évaluer et/ou traiter des maladies immunitaires chroniques
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
CN102304483A (zh) 2011-08-12 2012-01-04 北京金泰得生物科技股份有限公司 一株饲用屎肠球菌及其应用
KR101261872B1 (ko) 2011-08-23 2013-05-14 대한민국 (식품의약품안전처장) 장내 미생물 효소복합체 및 이의 제조방법
CA2848762C (fr) 2011-09-14 2021-07-27 Queen's University At Kingston Procede de traitement de troubles de l'appareil gastro-intestinal
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EA201490512A1 (ru) 2011-10-11 2014-09-30 Ачим Байотерапьютикс Аб Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека
FI126711B (fi) 2011-10-12 2017-04-13 Gut Guide Oy Serotoniinivajeeseen liittyvän terveysriskin arvioiminen
CN103082292B (zh) 2011-11-02 2015-03-04 深圳华大基因研究院 罗斯氏菌(Roseburia)在治疗和预防肥胖相关疾病中的应用
CN102373172B (zh) 2011-11-03 2013-03-20 北京龙科方舟生物工程技术有限公司 一株屎肠球菌及其应用
CA2892588A1 (fr) 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Bacteries d'origine humaine qui induisent la proliferation ou l'accumulation de lymphocytes t regulateurs
ES2408279B1 (es) 2011-12-15 2014-09-09 Universidad De Las Palmas De Gran Canaria Bacteria acido láctica probiótica
ITBG20120010A1 (it) 2012-02-24 2013-08-25 Milano Politecnico Dispositivo per l'addestramento chirurgico
ITMI20120471A1 (it) 2012-03-26 2013-09-27 Giovanni Mogna Composizione a base di ceppi di batteri bifidobacterium longum in grado di aiutare il prolungamento della vita
JP5792105B2 (ja) 2012-03-27 2015-10-07 森永乳業株式会社 ラクト−ｎ−ビオースｉの製造方法
EP2832859B1 (fr) 2012-03-30 2018-07-25 Ajinomoto Co., Inc. Bactérie induisant le diabète
WO2013154826A2 (fr) 2012-04-11 2013-10-17 Nestec Sa Procédés de diagnostic de diarrhée imminente
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
EP2836218A4 (fr) 2012-04-13 2015-10-21 Trustees Boston College Compositions prébiotiques et leurs procédés d'utilisation
WO2013171515A1 (fr) 2012-05-18 2013-11-21 Genome Research Limited Procédés et groupes
ES2436251B1 (es) 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
NZ703394A (en) 2012-06-04 2017-01-27 Centre For Digestive Diseases Compositions and methods for treating crohn’s disease and related conditions and infections
CN106620189B (zh) 2012-06-06 2021-11-19 上海交通大学 改善肠道菌群结构的方法及应用
EP2864355B1 (fr) 2012-06-25 2016-10-12 Orega Biotech Anticorps antagonistes de l'il-17
CA2877811C (fr) 2012-07-31 2019-07-23 Nestec S.A. Composition nutritionnelle pour promouvoir la sante musculosquelettique chez des patients souffrant de maladie intestinale inflammatoire non specifique (mici)
WO2014019271A1 (fr) 2012-08-01 2014-02-06 Bgi Shenzhen Biomarqueurs pour le diabète et utilisations correspondantes
KR101426276B1 (ko) * 2012-08-16 2014-08-05 주식회사한국야쿠르트 심장질환 및 뇌졸중을 유발하는 거품세포 형성 억제 및 혈관 병변 형성을 억제하는 활성을 가지는 락토바실러스 플란타룸 ｈｙ７７１２를 유효성분으로 함유하는 제품
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
EP2890808A4 (fr) 2012-08-29 2016-09-28 California Inst Of Techn Diagnostic et traitement du trouble du spectre autistique
KR20150046310A (ko) 2012-08-29 2015-04-29 샐릭스 파마슈티컬스 인코포레이티드 완화제 조성물 및 변비 및 관련 위장관 질병 및 증상 치료를 위한 방법
WO2014043593A2 (fr) 2012-09-13 2014-03-20 Massachusetts Institute Of Technology Profils d'administration de médicaments programmables de bactéries ciblées par une tumeur
KR101473058B1 (ko) 2012-09-19 2014-12-16 주식회사 쎌바이오텍 과민성 대장 증후군 예방 또는 치료용 조성물
CN103652322B (zh) 2012-09-21 2016-02-10 临沂思科生物科技有限公司 一种含乳酸菌的复合益生菌饲料添加剂的制备方法
EP2904096A1 (fr) 2012-10-03 2015-08-12 Metabogen AB Identification d'une personne ayant un risque d'athérosclérose et de maladies associées par le microbiome intestinal de la personne et prévention de telles maladies
FR2997091B1 (fr) 2012-10-22 2016-05-06 Fond Mediterranee Infection Utilisation d'un compose antioxydant pour la culture de bacteries sensibles a la tension en oxygene
US9839657B2 (en) 2012-10-30 2017-12-12 Deerland Enzymes, Inc. Prebiotic compositions comprising one or more types of bacteriophage
WO2014067976A1 (fr) 2012-10-30 2014-05-08 Nestec S.A. Compositions comprenant des microparticules et des probiotiques permettant d'apporter un effet immunitaire synergique
EP3345606A1 (fr) 2012-11-01 2018-07-11 Rijksuniversiteit Groningen Procédés et compositions pour stimuler les bactéries bénéfiques dans le tractus gastro-intestinal.
WO2014075745A1 (fr) 2012-11-19 2014-05-22 Université Catholique de Louvain Utilisation d'akkermansia pour le traitement de troubles métaboliques
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
SG10201704035TA (en) 2012-11-23 2017-06-29 Seres Therapeutics Inc Synergistic bacterial compositions and methods of production and use thereof
US20150297642A1 (en) 2012-11-26 2015-10-22 Thomas Julius Borody Compositions for the restoration of a fecal microbiota and methods for making and using them
US8993233B2 (en) 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
MX2015007550A (es) 2012-12-12 2017-02-02 Broad Inst Inc Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas.
PT2898075E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições de enzima melhorados para manipulação de sequências
US20140193464A1 (en) 2013-01-08 2014-07-10 Imagilin Technology, Llc Effects of probiotics on humans and animals under environmental or biological changes
EP2951283A4 (fr) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions et procédés
KR102222273B1 (ko) 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
EP2958575B1 (fr) 2013-02-22 2019-04-03 The Regents of The University of California Composition comprenant lactobacillus johnsonii 456 et son utilisation pour traiter ou prévenir des maladies
BR112015020819A2 (pt) 2013-03-05 2017-07-18 Academisch Ziekenhuis Groningen uso de faecalibacterium prausnitzii htf-f (dsm 26943) para supressão de inflamação
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
US20160040215A1 (en) 2013-03-14 2016-02-11 Seres Therapeutics, Inc. Methods for Pathogen Detection and Enrichment from Materials and Compositions
WO2014150094A1 (fr) 2013-03-15 2014-09-25 University Of Florida Research Foundation, Inc. Bactéries butyrogènes en tant que probiotiques pour le traitement de clostridium difficile
WO2014150139A1 (fr) 2013-03-15 2014-09-25 Microbiome Therapeutics, Llc. Fibre de cosse de soja activée
AU2014232370B2 (en) 2013-03-15 2018-11-01 Seres Therapeutics, Inc. Network-based microbial compositions and methods
CN103156888A (zh) 2013-03-18 2013-06-19 广州知光生物科技有限公司 脆弱拟杆菌在制备治疗炎症性肠病组合物中的应用
CN103142656A (zh) 2013-03-18 2013-06-12 广州知光生物科技有限公司 脆弱拟杆菌在制备防治结肠癌组合物中的应用
CN103146620A (zh) 2013-03-25 2013-06-12 广州知光生物科技有限公司 具有益生菌特性的脆弱拟杆菌
JP2014196260A (ja) 2013-03-29 2014-10-16 公立大学法人奈良県立医科大学 慢性閉塞性肺疾患の予防又は治療用組成物
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP2994161B1 (fr) 2013-05-10 2020-10-28 California Institute of Technology Prévention et traitement probiotiques du cancer du côlon
US10284649B2 (en) 2013-05-31 2019-05-07 Nec Corporation Distributed processing system
KR102093537B1 (ko) 2013-06-05 2020-04-23 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt), 조성물 및 제조방법
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US20160120915A1 (en) 2013-06-10 2016-05-05 New York University Methods for manipulating immune responses by altering microbiota
WO2014200334A1 (fr) 2013-06-14 2014-12-18 N.V. Nutricia Composition synbiotique pour le traitement d'infections chez des patients allergiques
WO2015003001A1 (fr) 2013-07-01 2015-01-08 The Washington University Procédés pour identifier des compléments qui augmentent la colonisation intestinale par une espèce bactérienne isolée, et compositions dérivées
WO2015003305A1 (fr) 2013-07-08 2015-01-15 吉瑞高新科技股份有限公司 Étui de cigarette électronique
JP2016530239A (ja) 2013-07-09 2016-09-29 ピュアテック ベンチャーズ、エルエルシー 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US20160192689A1 (en) 2013-07-31 2016-07-07 Wikifoods, Inc. Encapsulated functional food compositions
CN105658226B (zh) 2013-08-16 2019-05-14 港大科桥有限公司 使用益生菌治疗癌症的方法和组合物
CN103509741B (zh) 2013-08-22 2015-02-18 河北农业大学 布劳特菌auh-jld56及其在牛蒡苷元转化中的应用
CN104415060A (zh) 2013-08-30 2015-03-18 深圳华大基因科技有限公司 可食用组合物及其制备方法和用途
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
US10203329B2 (en) 2013-09-12 2019-02-12 The Johns Hopkins University Biofilm formation to define risk for colon cancer
US10058576B2 (en) 2013-10-03 2018-08-28 The Trustees Of The University Of Pennsylvania Compositions and methods comprising a defined microbiome and methods of use thereof
US10292413B2 (en) 2013-10-18 2019-05-21 Innovachildfood Ab Nutritionally balanced composite meal for infants and small children and a method of producing said meal
PL229020B1 (pl) 2013-11-13 2018-05-30 Inst Biotechnologii Surowic I Szczepionek Biomed Spolka Akcyjna Nowy szczep Bifidobacterium breve
KR102379658B1 (ko) 2013-11-25 2022-03-28 세레스 테라퓨틱스, 인코포레이티드 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CN103981115B (zh) 2013-12-24 2018-10-26 北京大伟嘉生物技术股份有限公司 一株高抗逆性屎肠球菌及其应用
CN103981117B (zh) 2013-12-24 2018-10-26 北京大伟嘉生物技术股份有限公司 一株高抗逆性屎肠球菌及其培养方法和应用
CN103820363B (zh) 2014-01-27 2016-02-24 福建省农业科学院生物技术研究所 一种屎肠球菌菌粉的制备与应用
CN103865846B (zh) 2014-02-27 2016-03-30 扬州绿保生物科技有限公司 一种屎肠球菌及其制备方法
CN103849590B (zh) 2014-03-25 2016-07-06 上海交通大学 一株耐酸短双歧杆菌BB8dpH及其应用
KR101683474B1 (ko) 2014-03-26 2016-12-08 주식회사 쎌바이오텍 과민성 대장 증후군 예방 또는 치료용 조성물
US9783858B2 (en) 2014-04-02 2017-10-10 Northwestern University Altered microbiome of chronic pelvic pain
KR101583546B1 (ko) 2014-04-09 2016-01-11 국립암센터 유전자 다형성을 이용한 소라페닙 치료에 대한 반응성 예측방법
WO2015156419A1 (fr) 2014-04-10 2015-10-15 Riken Compositions et méthodes d'induction de cellules th17
CN104195075B (zh) 2014-08-14 2017-04-19 生合生物科技股份有限公司 一种屎肠球菌ef08及包含它的饲料添加物和饲料
WO2015168534A1 (fr) 2014-05-02 2015-11-05 Novogy, Inc. Traitement thérapeutique de déséquilibres microbiens gastro-intestinaux par déplacement de microbes compétitif
AU2015257651B2 (en) 2014-05-08 2020-01-23 Panoptes Pharma Ges.M.B.H. Compounds for treating ophthalmic diseases and disorders
CN106573044B (zh) 2014-08-05 2020-01-21 深圳华大基因科技有限公司 真杆菌属在预防和治疗结直肠癌相关疾病中的用途
CN106687130B (zh) 2014-08-05 2020-01-21 深圳华大基因科技有限公司 真杆菌属在预防和治疗结直肠癌相关疾病中的用途
WO2016033439A2 (fr) 2014-08-28 2016-03-03 Yale University Compositions et méthodes pour le traitement d'une maladie ou d'un trouble inflammatoire
WO2016036615A1 (fr) 2014-09-03 2016-03-10 California Institute Of Technology Modulation à base microbienne de la biosynthèse de la sérotonine
CN104546942A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 多氏拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546932A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546935A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 多形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546933A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 粪拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546940A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 平常拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546934B (zh) 2014-09-30 2019-04-09 深圳华大基因科技有限公司 粪副拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
US10046030B2 (en) 2014-10-07 2018-08-14 University Of Virginia Patent Foundation Compositions and methods for preventing and treating infection
DK3209308T3 (da) 2014-10-24 2022-10-03 Evolve Biosystems Inc Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf
AU2015339290B8 (en) 2014-10-30 2021-08-26 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
EP3212207A4 (fr) 2014-10-30 2018-06-13 California Institute of Technology Compositions et procédés comprenant des bactéries pour l'amélioration du comportement dans les troubles neurodéveloppementaux
CA2964480A1 (fr) 2014-10-31 2016-05-06 Whole Biome Inc. Procedes et compositions se rapportant a un traitement microbien et au diagnostic de troubles
CN104435000A (zh) 2014-11-12 2015-03-25 江南大学 乳酸菌对支气管哮喘治疗中的应用
CN107249609A (zh) 2014-11-25 2017-10-13 纪念斯隆-凯特琳癌症中心 肠道微生物群和gvhd
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
HUE037476T2 (hu) 2014-12-23 2018-08-28 4D Pharma Res Ltd Pirin polipeptid és immunmodulálás
EP3065748B1 (fr) 2014-12-23 2017-11-22 4D Pharma Research Limited Une lignée de bacteroides thetaiotaomicron et son utilisation pour la réduction des inflammations
CN104560820B (zh) 2014-12-30 2017-10-20 杭州师范大学 屎肠球菌kq2.6及应用
US20160199425A1 (en) * 2015-01-08 2016-07-14 Nubiome, Inc. Treatment and Prophylaxis for Parkinson's Disease
KR20170128247A (ko) 2015-01-23 2017-11-22 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암 예방에서 단쇄 지방산의 용도
CN105982919A (zh) 2015-02-26 2016-10-05 王汉成 生物减速剂抗癌技术
WO2016139217A1 (fr) 2015-03-04 2016-09-09 Ab-Biotics, S.A. Composition comprenant un microbiote intestinal humain cultivé en conditions anaérobies
CA2976956A1 (fr) 2015-03-18 2016-09-22 Whole Biome Inc. Methodes et compositions se rapportant a un traitement microbien et au diagnostic de troubles cutanes
US20180078587A1 (en) 2015-03-18 2018-03-22 Trustees Of Tufts College Compositions and methods for preventing colorectal cancer
KR20160131237A (ko) * 2015-05-06 2016-11-16 한양대학교 산학협력단 C5-c8 유기산을 생산하는 신규 균주 및 이를 이용하여 c5-c8 유기산을 생산하는 방법
KR101745084B1 (ko) 2015-05-06 2017-06-09 한양대학교 산학협력단 메가스페라 헥사노이카 균주를 이용하여 헥사노익산을 생산하는 방법
CA2987129A1 (fr) 2015-06-01 2016-12-08 The University Of Chicago Traitement du cancer par manipulation de la flore microbienne commensale
MA41060B1 (fr) * 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3307288B1 (fr) 2015-06-15 2019-07-24 4D Pharma Research Limited Compositions comprenant des souches bactériennes
RS63089B1 (sr) 2015-06-15 2022-04-29 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PL3240554T3 (pl) 2015-06-15 2020-02-28 4D Pharma Research Limited Blautia stercosis i wexlerae do stosowania w leczeniu chorób zapalnych i autoimmunologicznych
US11771065B2 (en) 2015-08-20 2023-10-03 Api Holdings, Llc Formulations and methods for promoting honeybee health
CN105112333A (zh) 2015-08-31 2015-12-02 江南大学 一种具有良好肠道定殖能力的长双歧杆菌及筛选方法和应用
CA3003908A1 (fr) 2015-11-03 2017-05-11 The Brigham And Women's Hospital, Inc. Microbiote therapeutique pour le traitement et/ou la prevention de l'allergie alimentaire
MA41013B1 (fr) 2015-11-20 2018-07-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3380108B1 (fr) 2015-11-24 2022-11-16 Seres Therapeutics, Inc. Compositions bactériennes synthétiques
AU2016361583B2 (en) 2015-11-25 2021-05-13 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
CN108779434A (zh) 2016-01-11 2018-11-09 3Plw有限责任公司 被遗传修饰以分泌多糖降解酶的利用乳酸的细菌
PT3313423T (pt) 2016-03-04 2019-07-10 4D Pharma Plc Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral
EP4368254A2 (fr) 2016-03-14 2024-05-15 Holobiome, Inc. Modulation du microbiome intestinal pour traiter les troubles mentaux ou les maladies du système nerveux central
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
JP6898628B2 (ja) 2016-06-15 2021-07-07 国立大学法人広島大学 神経変性疾患治療剤
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
IT201600091033A1 (it) 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
WO2018094190A2 (fr) 2016-11-18 2018-05-24 Sanford Burnham Prebys Medical Discovery Institute Microbiote intestinal et traitement du cancer
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018112365A2 (fr) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Procédés de traitement du cancer colorectal et d'un mélanome en utilisant parabacteroides goldsteinii
WO2018112363A1 (fr) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Méthodes de traitement du cancer à l'aide de parabacteroides
CN106890196A (zh) 2017-04-07 2017-06-27 青岛东海药业有限公司 酪酸梭菌在制备预防或治疗帕金森病制剂中的应用
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2018229189A1 (fr) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprenant des souches bactériennes
HRP20220747T1 (hr) 2017-06-14 2022-10-14 4D Pharma Research Limited Pripravci koji sadrže bakterijske sojeve
AU2018298087A1 (en) 2017-07-05 2020-01-23 Evelo Biosciences, Inc. Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis
KR20210008393A (ko) 2018-05-11 2021-01-21 4디 파마 리서치 리미티드 세균 균주를 포함하는 조성물
EP3893905A1 (fr) 2018-12-12 2021-10-20 4D Pharma Research Limited Compositions comprenant des souches bactériennes

Also Published As

Publication number Publication date
CA3066561A1 (fr) 2018-12-20
PT3804737T (pt) 2022-08-29
US11779613B2 (en) 2023-10-10
HUE059249T2 (hu) 2022-11-28
MA53937A (fr) 2021-04-14
WO2018229216A1 (fr) 2018-12-20
AU2018283994A1 (en) 2020-02-06
MA49425A (fr) 2020-04-22
US11660319B2 (en) 2023-05-30
BR112019026667A2 (pt) 2020-06-23
RS60910B1 (sr) 2020-11-30
MD3804737T2 (ro) 2022-10-31
AU2018285453A1 (en) 2020-02-06
MX2021006456A (es) 2021-07-02
AU2021203891A1 (en) 2021-07-08
CN110913876A (zh) 2020-03-24
BR112019026677A2 (pt) 2020-06-30
EP3600364B1 (fr) 2020-08-05
WO2018229236A2 (fr) 2018-12-20
CY1123565T1 (el) 2022-03-24
JP2020523313A (ja) 2020-08-06
WO2018229236A3 (fr) 2019-03-07
TW201919667A (zh) 2019-06-01
IL271265A (en) 2020-01-30
US20200206280A1 (en) 2020-07-02
NZ760605A (en) 2022-03-25
DK3600364T3 (da) 2020-08-31
CY1125659T1 (el) 2024-02-16
HRP20220747T1 (hr) 2022-10-14
US20210315943A1 (en) 2021-10-14
JP6837581B2 (ja) 2021-03-03
NZ773323A (en) 2022-03-25
EP3638273A2 (fr) 2020-04-22
HRP20201629T1 (hr) 2020-12-25
NZ760654A (en) 2021-03-26
TW201919668A (zh) 2019-06-01
MA49010A (fr) 2020-02-05
IL271319A (en) 2020-01-30
CN111032061A (zh) 2020-04-17
SG11201912153VA (en) 2020-01-30
PL3600364T3 (pl) 2021-01-11
SG11201912156QA (en) 2020-01-30
MD3600364T2 (ro) 2020-12-31
CA3066557A1 (fr) 2018-12-20
CA3066561C (fr) 2022-07-19
RS63393B1 (sr) 2022-08-31
US20200215126A1 (en) 2020-07-09
CA3160116A1 (en) 2018-12-20
ES2917415T3 (es) 2022-07-08
SI3600364T1 (sl) 2020-10-30
ES2823053T3 (es) 2021-05-07
IL271265B (en) 2022-06-01
EP3804737B1 (fr) 2022-05-18
JP2022088641A (ja) 2022-06-14
AU2020204099A1 (en) 2020-07-09
TWI812624B (zh) 2023-08-21
AU2018285453B2 (en) 2020-03-19
LT3600364T (lt) 2020-10-26
DK3804737T3 (da) 2022-07-25
KR20200015575A (ko) 2020-02-12
KR20200018463A (ko) 2020-02-19
SI3804737T1 (sl) 2022-07-29
AU2018283994B2 (en) 2021-03-18
US11007233B2 (en) 2021-05-18
MA49010B1 (fr) 2020-11-30
PT3600364T (pt) 2020-10-19
LT3804737T (lt) 2022-07-11
KR102519483B1 (ko) 2023-04-10
IL292373A (en) 2022-06-01
JP2020523326A (ja) 2020-08-06
HUE052258T2 (hu) 2021-04-28
PL3804737T3 (pl) 2022-09-12
EP4104843A1 (fr) 2022-12-21
EP3600364A1 (fr) 2020-02-05
EP3804737A1 (fr) 2021-04-14
JP2021075556A (ja) 2021-05-20

Similar Documents

Publication Publication Date Title
MA53937B1 (fr) Compositions comprenant des souches bactériennes
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA41013A (fr) Compositions comprenant des souches bactériennes
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434A (fr) Compositions comprenant des souches bactériennes
MA41010A (fr) Compositions comprenant des souches bactériennes
MA42560A (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
MA44322A (fr) Compositions comprenant des souches bactériennes
MA42471A (fr) Compositions comprenant des souches bactériennes
MA42279A (fr) Compositions comprenant une souche bactérienne de blautia hydrogenotrophica pour l'utilisation pour la prevention ou le traitement de la diarrhee ou la constipation
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA49373B1 (fr) Compositions comprenant des souches bactériennes
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
MA44426B1 (fr) Compositions et méthodes pour diminier l'expression de tau
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA48939A (fr) Compositions comprenant des souches bactériennes
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA38369B1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
MA50273B1 (fr) Compositions comprenant des souches bactériennes
MA41059A (fr) Compositions comprenant des souches bactériennes
MA41104A (fr) Compositions comprenant des souches bactériennes
MA49300A (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
EA201992647A1 (ru) Композиции, содержащие бактериальные штаммы